Related Experiment Videos
Can virus therapy of human cancer be improved by apoptosis induction?
1St Joseph's Hospital, Department of Medicine, University of South Florida College of Medicine, Tampa 33677-4227, USA.
Abstract:
Direct virus inoculations and viral oncolysates may induce temporary remissions and prolong life with reduced tumor burden, or decrease relapse rates but fall short of curing human cancers. We propose: (i) investigations of Cassel's 73-T, an Ehrlich's mouse ascites carcinoma-adapted Newcastle disease virus (NDV) strain that so effectively reduced relapse rates in malignant melanoma if it is an admixture or a recombinant with a murine parvovirus; (ii) transfection of prostatic carcinoma cells with the TRMP gene; (iii) transfection of sarcoma cells with the fas gene followed by treatment with anti-fas monoclonal antibodies, and (iv) treatment of metastatic tumors with a parvovirus incorporating the apoptosis-inducer Ad5 E1A gene.Thus, replicating virions and haphazard generation of cytokines in the inoculated host could be replaced with transfection of single genes of well-defined, limited but selected efficacy.
Insights
Investigating novel viral therapies, including Newcastle disease virus (NDV) and parvovirus combinations, shows promise for enhancing cancer treatment efficacy and reducing relapse rates in various cancers.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Direct virus inoculations and viral oncolysates offer limited efficacy in curing human cancers, often resulting in temporary remissions and reduced tumor burden.
- Current viral therapies fall short of achieving complete cancer eradication and preventing relapse.
Purpose of the Study:
- To propose novel viral-based strategies for improved cancer treatment.
- To explore the potential of specific viral strains and gene modifications for enhanced anti-cancer activity.
Main Methods:
- Investigating Cassel's 73-T strain of Newcastle disease virus (NDV) as an admixture or recombinant with murine parvovirus for malignant melanoma.
- Proposing gene transfection of prostatic carcinoma cells with the TRMP gene.
- Suggesting transfection of sarcoma cells with the fas gene followed by anti-fas monoclonal antibody treatment.
- Proposing parvovirus treatment incorporating the Ad5 E1A gene for metastatic tumors.
Main Results:
- The proposed methods aim to replace replicating virions and random cytokine generation with targeted gene transfection for defined therapeutic effects.
- Specific viral-gene combinations are hypothesized to reduce relapse rates and improve treatment outcomes.
Conclusions:
- Novel viral and gene-based therapeutic approaches hold potential for more effective cancer treatment.
- Targeted gene delivery via viral vectors offers a promising alternative to traditional oncolytic virotherapy.